Integrated analysis of randomized controlled trials evaluating bortezomib + lenalidomide + dexamethasone or bortezomib + thalidomide + dexamethasone induction in transplant-eligible newly diagnosed multiple myeloma

OBJECTIVE: Providing the most efficacious frontline treatment for newly diagnosed multiple myeloma (NDMM) is critical for patient outcomes. No direct comparisons have been made between bortezomib + lenalidomide + dexamethasone (VRD) and bortezomib + thalidomide + dexamethasone (VTD) induction regime...

Descripción completa

Detalles Bibliográficos
Autores principales: Rosiñol, Laura, Hebraud, Benjamin, Oriol, Albert, Colin, Anne-Laurène, Ríos Tamayo, Rafael, Hulin, Cyrille, Blanchard, María Jesús, Caillot, Denis, Sureda, Anna, Hernández, Miguel Teodoro, Arnulf, Bertrand, Mateos, Maria-Victoria, Macro, Margaret, San-Miguel, Jesús, Belhadj, Karim, Lahuerta, Juan José, Garelik, M. Brigid, Bladé, Joan, Moreau, Philippe
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2023
Materias:
Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10652744/
https://www.ncbi.nlm.nih.gov/pubmed/38023148
http://dx.doi.org/10.3389/fonc.2023.1197340

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10652744/
https://www.ncbi.nlm.nih.gov/pubmed/38023148
http://dx.doi.org/10.3389/fonc.2023.1197340

Ejemplares similares